Storgate LLC Invests $686,000 in Sanofi $SNY

Storgate LLC acquired a new position in Sanofi (NASDAQ:SNY) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 14,166 shares of the company’s stock, valued at approximately $686,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Flagship Harbor Advisors LLC purchased a new stake in Sanofi during the fourth quarter worth $25,000. Measured Wealth Private Client Group LLC purchased a new stake in Sanofi during the third quarter worth $29,000. Palisade Asset Management LLC purchased a new stake in Sanofi during the third quarter worth $30,000. Annis Gardner Whiting Capital Advisors LLC boosted its holdings in Sanofi by 544.4% during the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 696 shares of the company’s stock worth $34,000 after buying an additional 588 shares in the last quarter. Finally, Larson Financial Group LLC boosted its holdings in Sanofi by 48.9% during the fourth quarter. Larson Financial Group LLC now owns 810 shares of the company’s stock worth $39,000 after buying an additional 266 shares in the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

Sanofi Stock Performance

SNY opened at $44.25 on Friday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. The company has a market cap of $107.28 billion, a price-to-earnings ratio of 12.36, a PEG ratio of 1.09 and a beta of 0.34. Sanofi has a 52-week low of $42.28 and a 52-week high of $52.68. The firm’s fifty day simple moving average is $45.14 and its two-hundred day simple moving average is $46.55.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. The ex-dividend date of this dividend was Monday, May 4th. This is a positive change from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. Sanofi’s payout ratio is 49.16%.

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Citigroup reissued a “neutral” rating on shares of Sanofi in a report on Monday, April 13th. Argus raised shares of Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, March 19th. BNP Paribas Exane downgraded shares of Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price target on the stock. in a report on Monday, April 20th. Finally, Wall Street Zen downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a report on Saturday, February 21st. Two equities research analysts have rated the stock with a Strong Buy rating, three have given a Buy rating and ten have assigned a Hold rating to the company. Based on data from MarketBeat.com, Sanofi has an average rating of “Hold” and an average target price of $51.00.

About Sanofi

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.